Head and neck carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A carcinoma that arises from the head and neck region. Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Head and neck carcinoma
- Therapeutic area
- Oncology
- head and neck carcinoma
- carcinoma of craniocervical region
- carcinoma of head and neck
- carcinoma of neck
- carcinoma of the head and neck
- craniocervical region carcinoma
- head and neck carcinoma
- neck carcinoma
- carcinoma of the neck
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0002038
- Parent condition
- MONDO:0004993
Related records
Broader conditions (11)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by etiologic mechanism
- Epithelial neoplasm
- Head and neck cancer
- Head and neck neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (136)
- ACTH-producing pituitary gland carcinoma
- Adenoid cystic carcinoma of oropharynx
- Ameloblastic carcinoma
- Aniridia 2
- Aniridia 3
- Carcinoma arising in nasal papillomatosis
- Carcinoma in situ of epiglottis
- Carcinoma in situ of hypopharynx
- Carcinoma in situ of nasopharynx
- Carcinoma in situ of oropharynx
- Carcinoma of floor of mouth
- Carcinoma of hard palate
- Carcinoma of lip
- Carcinoma of parotid gland
- Carcinoma of soft palate
- Ceruminous carcinoma
- Conjunctival squamous cell carcinoma
- Cornea squamous cell carcinoma
- Epiglottis cancer
- Ethmoid sinus adenocarcinoma
Trials (137)
- A Digital Intervention Protocol to Enhance Recovery After Head and Neck Surgery
- A Financial Intervention (Financial Compass) to Identify and Address Financial Hardship Among Head and Neck Cancer Patients, Financial Compass Trial
- A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial
- A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation
- A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
- A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
- A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
- Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District
- Accelerator-based BNCT (Boron Neutron Capture Therapy) for Head and Neck Carcinoma.
- Acupuncture-Like Transcutaneous Electrical Nerve Stimulation in Treating Radiation-Induced Xerostomia in Patients With Head and Neck Cancer
- AIOCC Italian Registry on Head and Neck Carcinomas
- An Exercise Prehabilitation Intervention for Improving Mobility and Recovery Outcomes in Patients Undergoing Head and Neck Cancer Surgery
- An Integrative Multi-Omic Characterization of Head and Neck Carcinogenesis, Progression and Recurrence
- Antibacterial Properties of Silicon Incorporated With Quaternary Ammonium Polyethylenimine Nanoparticles
- Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
- At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
- BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
- Bioelectrical Impedance Analysis in Estimating Body Composition in Patients With Stage I-IV Head and Neck Cancer Undergoing Radiation Therapy
Approved drugs (2)
Drugs in development (17)
- Berzosertib Phase 1
- Cesium CS-131 Early phase 1
- Chlorine dioxide Phase 2
- Cisplatin Phase 3
- Gabapentin Phase 3
- Indocyanine green Phase 2
- Ketamine Phase 1
- Methotrexate Phase 3
- Milademetan Phase 2
- Nivolumab Phase 3
- Nogapendekin alfa Phase 2
- Oxaliplatin Phase 2
- Pembrolizumab Phase 3
- Porfimer sodium Phase 2
- Ramucirumab Phase 2
- Talimogene laherparepvec Phase 1
- Vinflunine Phase 3